New drug shows promise for Hard-to-Treat blood cancer
NCT ID NCT05228470
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a drug called elranatamab in 39 Chinese patients with multiple myeloma that had stopped responding to at least three prior treatments. The drug works by helping the immune system attack cancer cells. The goal was to see if it could shrink tumors and control the disease for a period of time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Elranatamab (a drug that helps the immune system attack cancer cells)
- What this could lead to
- If successful, elranatamab could offer a new treatment option for Chinese patients with multiple myeloma that has stopped responding to other therapies.
- What could go wrong
- This is an early-phase trial with only 39 participants, so results may not apply to everyone. The drug can cause serious side effects like low blood cell counts and cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
39 people
The number who actually took part.
- Started
-
Dec 2021
- Finished
-
Sep 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of multiple myeloma (IMWG criteria, Rajkumar et al, 2014) * Measurable disease, as defined by at least 1 of the following: * Serum M-protein ≥0.5 g/dL * Urinary M-protein excretion ≥200 mg/24 hours * Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio * Refractory to at least one IMiD * Refractory to at least one PI * Refractory to at least one anti-CD38 antibody * Relapsed/refractory to last anti-myeloma regimen * ECOG performance status ≤2 * Adequate BM function characterized by the following: 1. Absolute neutrophil count ≥1.0 × 10\^9/L 2. Platelets ≥ 25 × 10\^9/L 3. Hemoglobin ≥8 g/dL * Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1 * Not pregnant and willing to use contraception Exclusion Criteria: * Smoldering multiple myeloma * Active Plasma cell leukemia * Amyloidosis * POEMS syndrome * Stem cell transplant or active GVHD within 12 weeks prior to enrollment. * Previous treatment with an anti-BCMA directed therapy * Impaired cardiovascular function or clinically significant cardiovascular diseases * Ongoing Grade ≥2 peripheral sensory or motor neuropathy. History of GBS or GBS variants, or history of any Grade ≥3 peripheral motor polyneuropathy. * Active HBV, HCV, SARS-CoV2, HIV, or any active, uncontrolled bacterial, fungal, or viral infection * Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ. * Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BCMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Gaobo Boren Hospital
Beijing, 100070, China
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, 350001, China
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510080, China
-
Harbin First Hospital
Harbin, Heilongjiang, 150010, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
-
Hematology Hospital, Chinese Academy of Medical Sciences
Tianjin, 300020, China
-
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, 510515, China
-
Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210008, China
-
Peking Union Medical College Hospital
Beijing, 100730, China
-
Peking University Third Hospital
Beijing, 100191, China
-
Shandong Provincial Hospital
Jinan, Shandong, 250021, China
-
Shenzhen Second People's Hosptial
Shenzhen, Guangdong, 518035, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510555, China
-
The First Affiliated Hospital of College of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cheap blood count ratios eyed as window into Myeloma's inflammatory grip
- Can a t-cell engager rescue myeloma that outsmarted CAR-T?
- Can myeloma treatment work without steroids?
- Double-Drug attack on Hard-to-Treat lymphomas
- Banking blood and bone marrow to decode plasma cell disorders
- Which scan sees hidden myeloma better: PET or MRI?